Evolution of randomized controlled trials and surrogacy of progression-free survival in advanced/metastatic urothelial cancer
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference72 articles.
1. Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advancedurothelial carcinoma;Agarwal;Clin. Genitourin. Cancer,2014
2. Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99];Albers;Ann. Oncol.,2011
3. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group;Bamias;J. Clin. Oncol.,2004
4. Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03);Bamias;Ann. Oncol.,2013
5. Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapy;Beer;Clin. Genitourin. Cancer,2008
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses;Journal of Neuro-Oncology;2023-09
2. Significance of second progression‐free survival in patients with advanced urothelial cancer who received platinum‐based combination chemotherapy followed by pembrolizumab;International Journal of Urology;2022-12-27
3. Progression-free survival is an adequate endpoint for clinical trials of locally advanced and metastatic urothelial carcinoma;Current Opinion in Urology;2022-07-15
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3